Charles N. York II - Sep 1, 2022 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
COO, CFO and Secretary
Signature
/s/ Charles N. York II
Stock symbol
DAWN
Transactions as of
Sep 1, 2022
Transactions value $
-$232,484
Form type
4
Date filed
9/6/2022, 07:54 PM
Previous filing
Aug 17, 2022
Next filing
Oct 5, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Sale -$199K -8.61K -2.65% $23.16 316K Sep 1, 2022 Direct F1, F2
transaction DAWN Common Stock Sale -$33.2K -1.39K -0.44% $23.80 314K Sep 1, 2022 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 15, 2021.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.7100 to $23.6800 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.7100 to $23.8500 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.